CA2749817A1 - Methods of determining patient response by measurement of her-2 expression - Google Patents
Methods of determining patient response by measurement of her-2 expression Download PDFInfo
- Publication number
- CA2749817A1 CA2749817A1 CA2749817A CA2749817A CA2749817A1 CA 2749817 A1 CA2749817 A1 CA 2749817A1 CA 2749817 A CA2749817 A CA 2749817A CA 2749817 A CA2749817 A CA 2749817A CA 2749817 A1 CA2749817 A1 CA 2749817A1
- Authority
- CA
- Canada
- Prior art keywords
- homodimers
- amount
- subject
- samples
- threshold level
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract 26
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 title claims 76
- 238000005259 measurement Methods 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 claims abstract 9
- 201000011510 cancer Diseases 0.000 claims abstract 9
- 239000000090 biomarker Substances 0.000 claims abstract 8
- 238000011282 treatment Methods 0.000 claims abstract 7
- -1 Bc12 Proteins 0.000 claims 18
- 239000003795 chemical substances by application Substances 0.000 claims 11
- 238000004393 prognosis Methods 0.000 claims 7
- 239000012472 biological sample Substances 0.000 claims 5
- 238000003556 assay Methods 0.000 claims 3
- 206010061289 metastatic neoplasm Diseases 0.000 claims 3
- 230000004850 protein–protein interaction Effects 0.000 claims 3
- 239000000523 sample Substances 0.000 claims 3
- 102100032311 Aurora kinase A Human genes 0.000 claims 2
- 102000052609 BRCA2 Human genes 0.000 claims 2
- 108700020462 BRCA2 Proteins 0.000 claims 2
- 102100021573 Bcl-2-binding component 3, isoforms 3/4 Human genes 0.000 claims 2
- 101150008921 Brca2 gene Proteins 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 102100031173 CCN family member 4 Human genes 0.000 claims 2
- 101100220616 Caenorhabditis elegans chk-2 gene Proteins 0.000 claims 2
- 102100021633 Cathepsin B Human genes 0.000 claims 2
- 102000038594 Cdh1/Fizzy-related Human genes 0.000 claims 2
- 108091007854 Cdh1/Fizzy-related Proteins 0.000 claims 2
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 claims 2
- 102000004328 Cytochrome P-450 CYP3A Human genes 0.000 claims 2
- 102100033189 Diablo IAP-binding mitochondrial protein Human genes 0.000 claims 2
- 101001046554 Dictyostelium discoideum Thymidine kinase 1 Proteins 0.000 claims 2
- 102100022334 Dihydropyrimidine dehydrogenase [NADP(+)] Human genes 0.000 claims 2
- 102100037024 E3 ubiquitin-protein ligase XIAP Human genes 0.000 claims 2
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 claims 2
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 claims 2
- 102100025403 Epoxide hydrolase 1 Human genes 0.000 claims 2
- 108010008599 Forkhead Box Protein M1 Proteins 0.000 claims 2
- 102100023374 Forkhead box protein M1 Human genes 0.000 claims 2
- 102100032340 G2/mitotic-specific cyclin-B1 Human genes 0.000 claims 2
- 102100036534 Glutathione S-transferase Mu 1 Human genes 0.000 claims 2
- 102100036528 Glutathione S-transferase Mu 3 Human genes 0.000 claims 2
- 102100029283 Hepatocyte nuclear factor 3-alpha Human genes 0.000 claims 2
- 101000798300 Homo sapiens Aurora kinase A Proteins 0.000 claims 2
- 101000971203 Homo sapiens Bcl-2-binding component 3, isoforms 1/2 Proteins 0.000 claims 2
- 101000971209 Homo sapiens Bcl-2-binding component 3, isoforms 3/4 Proteins 0.000 claims 2
- 101000777560 Homo sapiens CCN family member 4 Proteins 0.000 claims 2
- 101000898449 Homo sapiens Cathepsin B Proteins 0.000 claims 2
- 101001081590 Homo sapiens DNA-binding protein inhibitor ID-1 Proteins 0.000 claims 2
- 101000871228 Homo sapiens Diablo IAP-binding mitochondrial protein Proteins 0.000 claims 2
- 101000902632 Homo sapiens Dihydropyrimidine dehydrogenase [NADP(+)] Proteins 0.000 claims 2
- 101001077852 Homo sapiens Epoxide hydrolase 1 Proteins 0.000 claims 2
- 101000868643 Homo sapiens G2/mitotic-specific cyclin-B1 Proteins 0.000 claims 2
- 101001071694 Homo sapiens Glutathione S-transferase Mu 1 Proteins 0.000 claims 2
- 101001071716 Homo sapiens Glutathione S-transferase Mu 3 Proteins 0.000 claims 2
- 101001062353 Homo sapiens Hepatocyte nuclear factor 3-alpha Proteins 0.000 claims 2
- 101001046870 Homo sapiens Hypoxia-inducible factor 1-alpha Proteins 0.000 claims 2
- 101001034652 Homo sapiens Insulin-like growth factor 1 receptor Proteins 0.000 claims 2
- 101001044927 Homo sapiens Insulin-like growth factor-binding protein 3 Proteins 0.000 claims 2
- 101000624631 Homo sapiens M-phase inducer phosphatase 2 Proteins 0.000 claims 2
- 101000979629 Homo sapiens Nucleoside diphosphate kinase A Proteins 0.000 claims 2
- 101001051706 Homo sapiens Ribosomal protein S6 kinase beta-1 Proteins 0.000 claims 2
- 101000945477 Homo sapiens Thymidine kinase, cytosolic Proteins 0.000 claims 2
- 101000819111 Homo sapiens Trans-acting T-cell-specific transcription factor GATA-3 Proteins 0.000 claims 2
- 101000835093 Homo sapiens Transferrin receptor protein 1 Proteins 0.000 claims 2
- 101000742596 Homo sapiens Vascular endothelial growth factor C Proteins 0.000 claims 2
- 102100022875 Hypoxia-inducible factor 1-alpha Human genes 0.000 claims 2
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 claims 2
- 102100022708 Insulin-like growth factor-binding protein 3 Human genes 0.000 claims 2
- 102100023325 M-phase inducer phosphatase 2 Human genes 0.000 claims 2
- 102100023252 Nucleoside diphosphate kinase A Human genes 0.000 claims 2
- 102000036673 PRAME Human genes 0.000 claims 2
- 108060006580 PRAME Proteins 0.000 claims 2
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 claims 2
- 102100028588 Protein ZNRD2 Human genes 0.000 claims 2
- 102100024908 Ribosomal protein S6 kinase beta-1 Human genes 0.000 claims 2
- 101150001535 SRC gene Proteins 0.000 claims 2
- 101150093699 Scube2 gene Proteins 0.000 claims 2
- 102100028932 Signal peptide, CUB and EGF-like domain-containing protein 2 Human genes 0.000 claims 2
- 102100034838 Thymidine kinase, cytosolic Human genes 0.000 claims 2
- 102100021386 Trans-acting T-cell-specific transcription factor GATA-3 Human genes 0.000 claims 2
- 102100026144 Transferrin receptor protein 1 Human genes 0.000 claims 2
- 102000056172 Transforming growth factor beta-3 Human genes 0.000 claims 2
- 108090000097 Transforming growth factor beta-3 Proteins 0.000 claims 2
- 108050008367 Transmembrane emp24 domain-containing protein 7 Proteins 0.000 claims 2
- 102000008817 Trefoil Factor-1 Human genes 0.000 claims 2
- 108010088412 Trefoil Factor-1 Proteins 0.000 claims 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 2
- 102100038232 Vascular endothelial growth factor C Human genes 0.000 claims 2
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims 2
- 108700031544 X-Linked Inhibitor of Apoptosis Proteins 0.000 claims 2
- 108010048626 Y-Box-Binding Protein 1 Proteins 0.000 claims 2
- 102100022224 Y-box-binding protein 1 Human genes 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 2
- 101150113535 chek1 gene Proteins 0.000 claims 2
- 238000003745 diagnosis Methods 0.000 claims 2
- 239000000539 dimer Substances 0.000 claims 2
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 2
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 2
- 230000001394 metastastic effect Effects 0.000 claims 2
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 2
- 102000009310 vitamin D receptors Human genes 0.000 claims 2
- 108050000156 vitamin D receptors Proteins 0.000 claims 2
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 abstract 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 abstract 2
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 abstract 2
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 abstract 2
- 238000011269 treatment regimen Methods 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Hospice & Palliative Care (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14502909P | 2009-01-15 | 2009-01-15 | |
| US61/145,029 | 2009-01-15 | ||
| PCT/US2010/021272 WO2010083463A1 (en) | 2009-01-15 | 2010-01-15 | Methods of determining patient response by measurement of her-2 expression |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2749817A1 true CA2749817A1 (en) | 2010-07-22 |
Family
ID=42340111
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2749817A Abandoned CA2749817A1 (en) | 2009-01-15 | 2010-01-15 | Methods of determining patient response by measurement of her-2 expression |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US20100233732A1 (enExample) |
| EP (1) | EP2387717B1 (enExample) |
| JP (2) | JP2012515353A (enExample) |
| KR (1) | KR20110120890A (enExample) |
| CN (1) | CN102439452B (enExample) |
| AU (1) | AU2010204576A1 (enExample) |
| BR (1) | BRPI1007048A2 (enExample) |
| CA (1) | CA2749817A1 (enExample) |
| ES (1) | ES2526519T3 (enExample) |
| IL (1) | IL214067A0 (enExample) |
| SG (1) | SG172984A1 (enExample) |
| WO (1) | WO2010083463A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040229294A1 (en) | 2002-05-21 | 2004-11-18 | Po-Ying Chan-Hui | ErbB surface receptor complexes as biomarkers |
| US20040091850A1 (en) * | 2002-11-08 | 2004-05-13 | Travis Boone | Single cell analysis of membrane molecules |
| US7402398B2 (en) | 2003-07-17 | 2008-07-22 | Monogram Biosciences, Inc. | Measuring receptor homodimerization |
| WO2009070772A1 (en) | 2007-11-27 | 2009-06-04 | Monogram Biosciences, Inc. | Enhanced method for detecting and/or quantifying an analyte in a sample |
| US10416162B2 (en) | 2007-12-20 | 2019-09-17 | Monogram Biosciences, Inc. | Her2 diagnostic methods |
| ES2637411T3 (es) | 2008-12-01 | 2017-10-13 | Laboratory Corporation Of America Holdings | Métodos y ensayos para medir p95 Y/O p95 en una muestra y anticuerpos específicos para p95 |
| US11401344B2 (en) | 2008-12-01 | 2022-08-02 | Laboratory Corporation Of America Holdings | Methods for determining the likelihood of survival and for predicting likelihood of metastasis in cancer patients |
| ES2535723T3 (es) | 2009-01-15 | 2015-05-14 | Laboratory Corporation Of America Holdings | Métodos de determinación de la respuesta del paciente mediante la medición de Her-3 |
| WO2012015765A2 (en) | 2010-07-27 | 2012-02-02 | Genomic Health, Inc. | Method for using gene expression to determine prognosis of prostate cancer |
| TW201302793A (zh) | 2010-09-03 | 2013-01-16 | Glaxo Group Ltd | 新穎之抗原結合蛋白 |
| ES2701929T3 (es) | 2011-05-19 | 2019-02-26 | Laboratory Corp America Holdings | Métodos para determinar la probabilidad de supervivencia y para predecir la probabilidad de metástasis en el cáncer |
| FR2993668B1 (fr) * | 2012-07-17 | 2015-07-03 | Cisbio Bioassays | Methode theranostique basee sur la detection de dimeres her2-her2 |
| WO2014165855A1 (en) | 2013-04-05 | 2014-10-09 | Laboratory Corporation Of America Holdings | Systems and methods for facilitating diagnosis, prognosis and treatment of cancer based on detection of her3 activation |
| WO2016083364A1 (en) * | 2014-11-25 | 2016-06-02 | Ventana Medical Systems, Inc. | Proximity assays using chemical ligation and hapten transfer |
| WO2017014694A1 (en) * | 2015-07-23 | 2017-01-26 | National University Of Singapore | Wbp2 as a co-prognostic factor with her2 for stratification of patients for treatment |
| JP2019515252A (ja) | 2016-03-15 | 2019-06-06 | ラボラトリー コーポレイション オブ アメリカ ホールディングス | 細胞間のタンパク質相互作用を評価する方法 |
| PL3519437T3 (pl) | 2016-09-30 | 2022-01-17 | F. Hoffmann-La Roche Ag | Przeciwciała dwuswoiste przeciwko p95HER2 |
| JP6922444B2 (ja) * | 2016-11-11 | 2021-08-18 | コニカミノルタ株式会社 | 蛍光ナノ粒子を用いた、病理学的完全奏効（ｐＣＲ）の予測を支援するための検査支援方法 |
| WO2019241599A1 (en) * | 2018-06-14 | 2019-12-19 | Memorial Sloan Kettering Cancer Center | Methods for predicting responsiveness of lung cancer patients to her2-targeting therapies |
| KR102317202B1 (ko) * | 2018-10-19 | 2021-10-25 | 주식회사 프로티나 | 유방암 재발 예측 방법 |
| KR20230134232A (ko) | 2022-03-14 | 2023-09-21 | 부산대학교 산학협력단 | 백금계 항암제에 대한 난소암 환자의 약물 반응성 예측용 다중 바이오마커 조성물 및 이를 이용한 진단방법 |
Family Cites Families (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995026403A1 (en) * | 1994-03-29 | 1995-10-05 | Celltech Therapeutics Limited | Antibodies against e-selectin |
| SE9601676D0 (sv) * | 1996-04-30 | 1996-04-30 | Ulf Landegren | Improved probing of specific mucleic acids |
| US6335479B1 (en) * | 1998-10-13 | 2002-01-01 | Dai Nippon Printing Co., Ltd. | Protective sheet for solar battery module, method of fabricating the same and solar battery module |
| US6541214B1 (en) * | 1998-11-13 | 2003-04-01 | Oregon Heath Science University | N-terminally truncated HER-2/neu protein as a cancer prognostic indicator |
| US6627400B1 (en) * | 1999-04-30 | 2003-09-30 | Aclara Biosciences, Inc. | Multiplexed measurement of membrane protein populations |
| US6682887B1 (en) * | 1999-04-30 | 2004-01-27 | Aclara Biosciences, Inc. | Detection using degradation of a tagged sequence |
| US20040248150A1 (en) * | 1999-04-02 | 2004-12-09 | Sharat Singh | Methods employing oligonucleotide-binding e-tag probes |
| US6322980B1 (en) * | 1999-04-30 | 2001-11-27 | Aclara Biosciences, Inc. | Single nucleotide detection using degradation of a fluorescent sequence |
| US6514700B1 (en) * | 1999-04-30 | 2003-02-04 | Aclara Biosciences, Inc. | Nucleic acid detection using degradation of a tagged sequence |
| US20030235832A1 (en) * | 2000-06-21 | 2003-12-25 | Ahmed Chenna | Multiplexed analysis by chromatographic separation of molecular tags |
| US6673550B2 (en) * | 1999-04-30 | 2004-01-06 | Aclara Biosciences, Inc. | Electrophoretic tag reagents comprising fluorescent compounds |
| US7001725B2 (en) * | 1999-04-30 | 2006-02-21 | Aclara Biosciences, Inc. | Kits employing generalized target-binding e-tag probes |
| US7037654B2 (en) * | 1999-04-30 | 2006-05-02 | Aclara Biosciences, Inc. | Methods and compositions for enhancing detection in determinations employing cleavable electrophoretic tag reagents |
| US20030092012A1 (en) * | 2001-11-09 | 2003-05-15 | Ahmed Chenna | Methods for detecting a plurality of analytes by chromatography |
| US6649351B2 (en) * | 1999-04-30 | 2003-11-18 | Aclara Biosciences, Inc. | Methods for detecting a plurality of analytes by mass spectrometry |
| US6162593A (en) * | 1999-10-26 | 2000-12-19 | Wyatt; Marion F. | Diisopropylbenzene containing solvent and method of developing flexographic printing plates |
| DE19963849A1 (de) * | 1999-12-30 | 2001-07-12 | Giesecke & Devrient Gmbh | Datenträger mit gedrucktem Sicherheitselement |
| US7306904B2 (en) * | 2000-02-18 | 2007-12-11 | Olink Ab | Methods and kits for proximity probing |
| US6743911B2 (en) * | 2000-03-14 | 2004-06-01 | Shell Oil Company | Process for the carbonylation of pentenenitrile |
| GB0007911D0 (en) * | 2000-03-30 | 2000-05-17 | Novartis Ag | Organic compounds |
| US7160735B2 (en) * | 2000-04-28 | 2007-01-09 | Monogram Biosciences, Inc. | Tagged microparticle compositions and methods |
| US7771929B2 (en) * | 2000-04-28 | 2010-08-10 | Monogram Biosciences, Inc. | Tag library compounds, compositions, kits and methods of use |
| US7537938B2 (en) * | 2000-04-28 | 2009-05-26 | Monogram Biosciences, Inc. | Biomarker detection in circulating cells |
| US7255999B2 (en) * | 2001-05-21 | 2007-08-14 | Monogram Biosciences, Inc. | Methods and compositions for analyzing proteins |
| US20040067498A1 (en) * | 2000-04-28 | 2004-04-08 | Ahmed Chenna | Detection of nucleic acid sequences by cleavage and separation of tag-containing structures |
| US20030207300A1 (en) * | 2000-04-28 | 2003-11-06 | Matray Tracy J. | Multiplex analytical platform using molecular tags |
| EP1309717A1 (en) * | 2000-08-08 | 2003-05-14 | Aclara BioSciences, Inc. | Multiplexed enzymatic assays |
| ES2394293T3 (es) * | 2001-02-28 | 2013-01-30 | Bio Life Science Forschungs- Und Entwicklungsges.M.B.H. | Vacuna contra cánceres que están asociados con el oncogén HER-2/neu |
| US7183388B2 (en) * | 2001-03-30 | 2007-02-27 | The Regents Of The University Of California | Anti-MUC-1 single chain antibodies for tumor targeting |
| WO2002094998A2 (en) * | 2001-05-21 | 2002-11-28 | Aclara Biosciences, Inc. | Analyzing phosphorylated proteins |
| US7358052B2 (en) * | 2001-05-26 | 2008-04-15 | Monogram Biosciences, Inc. | Catalytic amplification of multiplexed assay signals |
| US7446185B2 (en) * | 2001-07-18 | 2008-11-04 | The Regents Of The University Of California | Her2/neu target antigen and use of same to stimulate an immune response |
| US20040241688A1 (en) * | 2001-07-19 | 2004-12-02 | Cuneyt Bukusoglu | Human tissue specific drug screening procedure |
| GB2378245A (en) * | 2001-08-03 | 2003-02-05 | Mats Nilsson | Nucleic acid amplification method |
| WO2003033741A1 (en) * | 2001-10-16 | 2003-04-24 | Aclara Biosciences, Inc. | Universal e-tag primer and probe compositions and methods |
| US7045311B2 (en) * | 2001-10-25 | 2006-05-16 | Monogram Biosciences, Inc. | Whole cell assay systems for cell surface proteases |
| US6659577B2 (en) * | 2001-12-06 | 2003-12-09 | Hewlett-Packard Development Company, L.P. | Dual flat springs for tool-less slide installation |
| US7135174B2 (en) * | 2002-01-07 | 2006-11-14 | Amgen Fremont, Inc. | Antibodies directed to PDGFD and uses thereof |
| KR101048894B1 (ko) * | 2002-02-26 | 2011-07-13 | 시그마타우 인두스트리에 파르마슈티케 리우니테 에스.피.에이. | 항-인간 테나신 단클론 항체 |
| US6949347B2 (en) * | 2002-03-05 | 2005-09-27 | Aclara Biosciences, Inc. | Multiplex analysis using membrane-bound sensitizers |
| EP3115470B1 (en) * | 2002-03-13 | 2018-07-18 | Genomic Health, Inc. | Gene expression profiling in biopsied tumor tissues |
| WO2003085374A2 (en) * | 2002-04-02 | 2003-10-16 | Aclara Biosciences, Inc. | Multiplexed assays using electrophoretically separated molecular tags |
| US7332580B2 (en) * | 2002-04-05 | 2008-02-19 | The Regents Of The University Of California | Bispecific single chain Fv antibody molecules and methods of use thereof |
| US20040248151A1 (en) * | 2002-04-05 | 2004-12-09 | Ventana Medical Systems, Inc. | Method for predicting the response to HER2-directed therapy |
| US20040229293A1 (en) * | 2002-05-21 | 2004-11-18 | Po-Ying Chan-Hui | Surface receptor complexes as biomarkers |
| US20040229380A1 (en) * | 2002-05-21 | 2004-11-18 | Po-Ying Chan-Hui | ErbB heterodimers as biomarkers |
| US20090111127A1 (en) * | 2002-05-21 | 2009-04-30 | Monogram Biosciences Inc. | Surface Receptor Complexes as Biomarkers |
| US7402397B2 (en) * | 2002-05-21 | 2008-07-22 | Monogram Biosciences, Inc. | Detecting and profiling molecular complexes |
| US20040229299A1 (en) * | 2002-05-21 | 2004-11-18 | Badal M. Youssouf | Intracellular complexes as biomarkers |
| US20040229294A1 (en) * | 2002-05-21 | 2004-11-18 | Po-Ying Chan-Hui | ErbB surface receptor complexes as biomarkers |
| US20040175765A1 (en) * | 2002-07-05 | 2004-09-09 | Sharat Singh | Cell-screening assay and composition |
| PT2263691E (pt) * | 2002-07-15 | 2012-11-12 | Hoffmann La Roche | Tratamento de cancro com o anticorpo anti-erbb2 monoclonal humanizado recombinante 2c4 (rhumab 2c4) |
| CN1672054A (zh) * | 2002-07-25 | 2005-09-21 | 阿克拉若生物科学公司 | 检测受体寡聚化 |
| JP2006508907A (ja) * | 2002-07-26 | 2006-03-16 | アクララ バイオサイエンシーズ， インコーポレイテッド | 親油性電気泳動プローブ |
| US20040091850A1 (en) * | 2002-11-08 | 2004-05-13 | Travis Boone | Single cell analysis of membrane molecules |
| BRPI0408950A (pt) * | 2003-04-01 | 2006-03-28 | Monogram Biosciences Inc | método para determinar a situação de doença de um paciente, e, método para selecionar um paciente para tratamento de um cáncer com um ou mais medicamentos de ação dimérica |
| US20100291594A1 (en) * | 2003-07-17 | 2010-11-18 | Laboratory Corporation Of America Holdings | ErbB Surface Receptor Complexes as Biomarkers |
| US7402398B2 (en) * | 2003-07-17 | 2008-07-22 | Monogram Biosciences, Inc. | Measuring receptor homodimerization |
| US20060204966A1 (en) * | 2003-08-01 | 2006-09-14 | Spector Neil L | Treatment of cancers expressing p95 erbb2 |
| EP1673399B1 (en) * | 2003-08-11 | 2017-04-05 | Monogram BioSciences, Inc. | Detecting and profiling molecular complexes |
| EP1664716A4 (en) * | 2003-08-15 | 2008-08-13 | Smithkline Beecham Corp | CANCER BIOMARKERS |
| US20050106571A1 (en) * | 2003-10-02 | 2005-05-19 | The Regents Of The University Of California | Mammalian T1R3 sweet taste receptors |
| WO2005037071A2 (en) * | 2003-10-14 | 2005-04-28 | Monogram Biosciences, Inc. | Receptor tyrosine kinase signaling pathway analysis for diagnosis and therapy |
| JP4011100B2 (ja) * | 2004-07-09 | 2007-11-21 | 中外製薬株式会社 | 抗グリピカン３抗体 |
| WO2006044748A2 (en) * | 2004-10-15 | 2006-04-27 | Monogram Biosciences, Inc. | RESPONSE PREDICTORS FOR ErbB PATHWAY-SPECIFIC DRUGS |
| WO2006137932A2 (en) * | 2004-11-03 | 2006-12-28 | Leucadia Technologies, Inc. | Homogeneous analyte detection |
| US7939267B2 (en) * | 2004-11-04 | 2011-05-10 | Laboratory Corporation Of America Holdings | Detection of activation of endothelial cells as surrogate marker for angiogenesis |
| US7862995B2 (en) * | 2004-12-10 | 2011-01-04 | Targeted Molecular Diagnostics | Methods and materials for predicting responsiveness to treatment with dual tyrosine kinase inhibitor |
| US20060212956A1 (en) * | 2005-03-14 | 2006-09-21 | Genentech, Inc. | Animal model of ligand activated HER2 expressing tumors |
| JP2006316040A (ja) * | 2005-05-13 | 2006-11-24 | Genentech Inc | Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法 |
| US7700299B2 (en) * | 2005-08-12 | 2010-04-20 | Hoffmann-La Roche Inc. | Method for predicting the response to a treatment |
| CN1928563B (zh) * | 2005-09-09 | 2010-04-28 | 上海张江生物技术有限公司 | 乳腺癌的免疫组化诊断试剂盒和测试片 |
| WO2009070772A1 (en) * | 2007-11-27 | 2009-06-04 | Monogram Biosciences, Inc. | Enhanced method for detecting and/or quantifying an analyte in a sample |
| CN101230390A (zh) * | 2007-12-07 | 2008-07-30 | 湖北大学 | 一种用于妇科恶性肿瘤早期筛选的基因芯片及其检测方法 |
| US10416162B2 (en) * | 2007-12-20 | 2019-09-17 | Monogram Biosciences, Inc. | Her2 diagnostic methods |
| ES2637411T3 (es) * | 2008-12-01 | 2017-10-13 | Laboratory Corporation Of America Holdings | Métodos y ensayos para medir p95 Y/O p95 en una muestra y anticuerpos específicos para p95 |
| ES2535723T3 (es) * | 2009-01-15 | 2015-05-14 | Laboratory Corporation Of America Holdings | Métodos de determinación de la respuesta del paciente mediante la medición de Her-3 |
-
2010
- 2010-01-15 BR BRPI1007048A patent/BRPI1007048A2/pt not_active Application Discontinuation
- 2010-01-15 JP JP2011546408A patent/JP2012515353A/ja not_active Withdrawn
- 2010-01-15 EP EP10732178.8A patent/EP2387717B1/en not_active Revoked
- 2010-01-15 ES ES10732178.8T patent/ES2526519T3/es active Active
- 2010-01-15 US US12/688,766 patent/US20100233732A1/en not_active Abandoned
- 2010-01-15 CA CA2749817A patent/CA2749817A1/en not_active Abandoned
- 2010-01-15 SG SG2011051000A patent/SG172984A1/en unknown
- 2010-01-15 CN CN201080009544.4A patent/CN102439452B/zh not_active Expired - Fee Related
- 2010-01-15 WO PCT/US2010/021272 patent/WO2010083463A1/en not_active Ceased
- 2010-01-15 KR KR1020117018898A patent/KR20110120890A/ko not_active Withdrawn
- 2010-01-15 AU AU2010204576A patent/AU2010204576A1/en not_active Abandoned
-
2011
- 2011-07-13 IL IL214067A patent/IL214067A0/en unknown
-
2014
- 2014-01-17 JP JP2014006601A patent/JP5615986B2/ja active Active
- 2014-07-02 US US14/322,317 patent/US20140370523A1/en not_active Abandoned
-
2016
- 2016-06-15 US US15/183,151 patent/US20170082626A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2010083463A1 (en) | 2010-07-22 |
| EP2387717A4 (en) | 2012-09-26 |
| US20170082626A1 (en) | 2017-03-23 |
| JP2014074724A (ja) | 2014-04-24 |
| BRPI1007048A2 (pt) | 2016-02-10 |
| JP2012515353A (ja) | 2012-07-05 |
| US20100233732A1 (en) | 2010-09-16 |
| CN102439452B (zh) | 2015-04-15 |
| JP5615986B2 (ja) | 2014-10-29 |
| AU2010204576A1 (en) | 2011-09-01 |
| ES2526519T3 (es) | 2015-01-13 |
| EP2387717A1 (en) | 2011-11-23 |
| IL214067A0 (en) | 2011-08-31 |
| US20140370523A1 (en) | 2014-12-18 |
| WO2010083463A9 (en) | 2010-12-23 |
| CN102439452A (zh) | 2012-05-02 |
| EP2387717B1 (en) | 2014-12-10 |
| SG172984A1 (en) | 2011-08-29 |
| KR20110120890A (ko) | 2011-11-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2749817A1 (en) | Methods of determining patient response by measurement of her-2 expression | |
| JP2012515353A5 (enExample) | ||
| Sueta et al. | Clinical significance of pretherapeutic Ki67 as a predictive parameter for response to neoadjuvant chemotherapy in breast cancer; is it equally useful across tumor subtypes? | |
| AU2004258085B2 (en) | Expression profile algorithm and test for cancer prognosis | |
| Villaflor et al. | Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer | |
| Ignatiadis et al. | Understanding the molecular basis of histologic grade | |
| Lee et al. | Circulating tumor cells in breast cancer: applications in personalized medicine | |
| Okegawa et al. | Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer | |
| Garczyk et al. | AGR3 in breast cancer: prognostic impact and suitable serum-based biomarker for early cancer detection | |
| Zhang et al. | Ki‐67 index, progesterone receptor expression, histologic grade and tumor size in predicting breast cancer recurrence risk: A consecutive cohort study | |
| WO2008151072A1 (en) | Multigene prognostic assay for lung cancer | |
| Curtit et al. | Prognostic and predictive indicators in early-stage breast cancer and the role of genomic profiling: Focus on the Oncotype DX® Breast Recurrence Score Assay | |
| Jia et al. | The combined ratio of estrogen, progesterone, Ki‐67, and P53 to predict the recurrence of endometrial cancer | |
| Zhai et al. | The nuclear expression of poly (ADP-ribose) polymerase-1 (PARP1) in invasive primary breast tumors is associated with chemotherapy sensitivity | |
| Wang et al. | Early evaluation of circulating tumor DNA as marker of therapeutic efficacy and prognosis in breast cancer patients during primary systemic therapy | |
| Deng et al. | Circulating tumor cells in gastric cancer: developments and clinical applications | |
| Yue et al. | RT-qPCR is helpful to distinguish the clinicopathological features of HER2 immunohistochemistry 0 and 1+ | |
| Laufer et al. | Low Alanine Aminotransferase, as a Marker of Sarcopenia and Frailty, Is Associated with Shorter Survival Among Prostate Cancer Patients and Survivors. A Retrospective Cohort Analysis of 4064 Patients | |
| Berse et al. | Molecular diagnostic testing in breast cancer | |
| Siddappa et al. | Gene expression analysis to detect disseminated tumor cells in the bone marrow of triple-negative breast cancer patients predicts metastatic relapse | |
| Wang et al. | Prognostic value of osteopontin expression in esophageal squamous cell carcinoma: A meta-analysis | |
| Rausch et al. | Muscle-invasive bladder cancer is characterized by overexpression of thymidine kinase 1 | |
| TWI817224B (zh) | 用於預測乳癌預後情形的方法及套組 | |
| Mazouni et al. | A nomogram to predict individual prognosis in node-negative breast carcinoma | |
| Guldvik et al. | Low blood levels of LRG1 before radical prostatectomy identify patients with high risk of progression to castration-resistant prostate cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20140708 |
|
| FZDE | Discontinued |
Effective date: 20191023 |
|
| FZDE | Discontinued |
Effective date: 20191023 |